Ludwig Cancer Research recently announced the appointment of Pat Morin, PhD, as Deputy Scientific Director of its international nonprofit organization, the Ludwig Institute for Cancer Research. Dr. Morin joins Ludwig from the University of Pennsylvania, where he has served as Executive Director for Strategic Alliances at the Abramson Cancer Center since 2016 and as Adjunct Professor at the Perelman School of Medicine since 2017.
Pat Morin, PhD
Chi Van Dang, MD, PhD
“Pat is perfectly suited to his new post at Ludwig Cancer Research,” said Chi Van Dang, MD, PhD, Ludwig Institute’s Scientific Director. “Not only is he an accomplished cancer researcher, but he also has a demonstrated flair for catalyzing team science to tackle tough scientific questions, which was apparent in his able leadership of the AACR Stand Up to Cancer initiative. His experience at the Abramson Cancer Center stimulating drug discovery through a partnership of four cancer centers will doubtless be an asset to Ludwig, as we place a renewed emphasis on team efforts to address the most pressing problems of cancer care. I very much look forward to working with him to advance Ludwig’s life-changing science.”
New Duties and Objectives
As deputy scientific director, Dr. Morin will work with Dr. Dang and the Ludwig Institute’s President and Chief Executive Officer Ed McDermott in directing and coordinating basic science and clinical research activities, overseeing the establishment and maintenance of the Institute’s infrastructure and the selection and review of scientific and clinical staff. He will also assist in the development and implementation of the Institute’s strategic and policy initiatives and help manage research collaborations both within Ludwig Cancer Research and with other organizations and individual researchers. Additionally, Dr. Morin will serve as Program Director for major research projects funded by external grants.
“The Ludwig Institute has been truly transformative in its approach to funding innovative cancer research, and its impact has been immeasurable,” said Dr. Morin. “I am honored and excited to join the Ludwig community, and I look forward to working with the Ludwig executive team, the Ludwig Scientific Advisory Committee and Board, and with Ludwig scientists to support groundbreaking research and advance Ludwig’s mission to improve the prevention and treatment of all cancers.”
